Categoria: Abstract

Background The prognostic impact of variant allele frequency (VAF) on clinical outcome in BRAFV600 mutated metastatic melanoma patients (MMPs) receiving BRAF (BRAFi) and MEK inhibitors (MEKi) is unclear. Materials and methods A cohort of MMPs receiving first line BRAFi and MEKi was identified by inspecting dedicated databases of three Italian Melanoma Intergroup centres. VAF was...

Background Immunotherapy has improved the survival of patients with stage IV melanoma. In responders, clinical benefits may be long-lasting and persist even after treatment discontinuation. The optimal duration of anti-PD1 (anti-Programmed cell death-1) therapy in metastatic melanoma patients remains to be elucidated. Moreover, limited data are available on clinical outcomes of patients that discontinued anti-PD1...

Background The clinical value of an expert pathological review in patients with an atypical melanocytic lesion diagnosis remains unclear. Herein, we evaluate its impact in a prospective clinical study. Methods Patients with newly diagnosed or suspected atypical melanocytic proliferations and challenging skin tumours were reviewed prospectively by a specialised dermatopathologist through the nationwide ‘Second Opinion...

Background Immunotherapy and targeted BRAF/MEK inhibitors (i) have revolutionised the systemic management of advanced melanoma. Given the role of stereotactic radiosurgery (SRS) in the local management of brain metastases, we sought to evaluate clinical outcomes in patients with melanoma brain metastases (MBM) treated with SRS and various systemic therapies. Methods Patients were included if MBM...

Abstract The current evidence on paediatric melanoma is heterogeneous, especially regarding the prognosis of different histological subtypes. We sought to systematically review the evidence on paediatric melanoma, highlighting the major sources of heterogeneity and focusing on available data on single patients. A systematic search was performed from 1948 to 25 January 2021. Only studies reporting...

Background People with a previous melanoma are at increased risk of developing another primary melanoma when compared with the general population. Understanding risk factors associated with multiple primary melanomas can inform patient education and tailored surveillance. Objectives We conducted a systematic review and meta-analysis to examine risk factors for subsequent primary melanoma. Methods A systematic...

Objectives To identify prognostic models for melanoma survival, recurrence and metastasis among American Joint Committee on Cancer stage I and II patients postsurgery; and evaluate model performance, including overall survival (OS) prediction. Design Systematic review and narrative synthesis. Data sources Searched MEDLINE, Embase, CINAHL, Cochrane Library, Science Citation Index and grey literature sources including cancer...

Purpose To provide guidance to clinicians regarding the use of systemic therapy for melanoma. Methods American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature. Results The updated review identified 21 additional randomized trials. Updated recommendations Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB...

Abstract In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone. Ninety-two...

Background NIVO + RELA and NIVO + IPI are approved as dual checkpoint inhibitor, 1L treatment options for patients (pts) with advanced melanoma based on results from the RELATIVITY-047 (NIVO + RELA vs NIVO; enrollment, 2018–2020) and CheckMate 067 (NIVO + IPI or NIVO vs IPI; enrollment, 2013–2014) trials, respectively. However, there is no head-to-head...